Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates

Group 1 - Twist Bioscience reported a quarterly loss of $0.53 per share, better than the Zacks Consensus Estimate of a loss of $0.62, and an improvement from a loss of $0.75 per share a year ago, resulting in an earnings surprise of 14.52% [1] - The company achieved revenues of $88.71 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.04%, and showing growth from year-ago revenues of $71.5 million [2] - Over the last four quarters, Twist Bioscience has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Group 2 - The stock has gained approximately 12.7% since the beginning of the year, outperforming the S&P 500's gain of 2.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.60 on revenues of $92.12 million, and for the current fiscal year, it is -$2.27 on revenues of $372.96 million [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Twist Bioscience belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Twist Bioscience is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]